Halomon 1 is an acyclic pentahalogenated terpene isolated in pure form as a major component of the organic extracts of red algae Portieria hornemannii and characterised by X-ray crystallography by Boyd in 1992. 1 Halomon's biological profile -initially found to display highly differential cytotoxicity against a diverse panel of human tumor cell lines, 1 and also shown more recently to be an inhibitor of DNA methyl transferase 1 2 -has attracted much interest, 3 but there is a lack of a reliable natural source from the algae due to site-to-site and temporal variations in terpene content. 4 Synthetic efforts have resulted in the successful synthesis of halomon, but only in racemic form and as a mixture of stereoisomers, thereby requiring subsequent separation. 5, 6 There is therefore a clear need for an asymmetric and stereoselective strategy to access halomon and its related congeners 4, 7 for further biological evaluation. However, the introduction of each of the five halogens via site-selective functionalisations, including asymmetric fashioning of the two halogen-bearing stereocentres and installation of the vinyl chloride offers significant synthetic challenge.
Scheme 1. Halomon 1 and its proposed biogenesis from myrcene 2.
Halomon 1 and its related congeners are considered to arise biogenetically via enzyme mediated Markovnikov addition of BrCl to the Δ 1 , Δ 6 and/or C-3 methylene double bonds of myrcene 2 followed by elimination of HBr and/or HCl (Scheme 1, halomon only). 8, 9, 10 With halomon 1 being isolated as a single enantiomer compound this implicates the intermediacy of enantiopure bromonium ions as promoted by bromoperoxidase in the algae.
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However, despite the recent rapid advance in asymmetric olefin halogenation methods, 12 a general method for direct enantioselective bromonium ion formation on one face of an isolated alkene followed by intermolecular regioselective and stereospecific capture with a nucleophile does not yet exist, 13 thus precluding attempted asymmetric synthesis of halomon 1 from myrcene 2 in this fashion.
On the other hand, we 14 and Denmark 15 13 C NMR spectra for compounds 5-7, 9-10, 12/13 mix, (3R,6S,7S)-3 and (3R,6R,7R)-3; X-ray crystallographic details for 6 and (3R,6S,7S)-3. * c.braddock@imperial.ac.uk Our studies commenced by using isoprene 4 as a model for the eastern portion of halomon, with a view to dihydroxylating known dibromide 5 into dibromodiol 6 (Table 1) . However, we were aware that there have been no reports of a dihydroxylation of any kind on a 2-alkyl-1,4-dibromo-but-2-ene such as dibromide 5. Thus, isoprene was dibrominated according to the method of Alexakis 19 giving the 1,4-dibromide 5 as a 94:6 E:Z mixture §, ¶ and dihydroxylation conditions were investigated (Table 1) . Attempted Sharpless asymmetric dihydroxylation (entry 1) of dibromide 5 with AD-mix-β and added methanesulphonamide 16 failed, however, where the substrate was consumed but no diol 6 was detected, and characteristic signals for epoxides could be observed in the 1 H NMR spectrum of the crude material.
¥ The limited literature precedent for osmium catalysed asymmetric dihydroxylation of allylic bromides suggests that NaHCO 3 -buffered AD-mix can suppress the unwanted pathways of hydrolysis of the starting material and base mediated ring-closure of the bromohydrin product to an epoxide. 20 However, attempts to apply these conditions to the conversion of dibromide 5 into diol 6 also failed (entry 2). The use of other reported protocols for allylic bromides (entry 3) 21 Dibromotetrol (3R,6S,7S)-3 proved to be crystalline, and the X-ray crystal structure (Figure 1 ) confirmed the original sense of induction in the Sharpless asymmetric dihydroxylation as well as all other relative and absolute configurations.
In conclusion we have demonstrated a successful asymmetric dihydroxylation-dibromination-dihydroxylation sequence employing in situ protection of diols as boronate esters during the dihydroxylation reactions to rapidly assemble the first enantiopure hexafunctionalised myrcene derivative in just four steps. This concise asymmetric sequence provides an advanced intermediate for the targeted synthesis of halomon 1 via subsequent stereospecific transformations (vide supra), 14 where both stereogenic centres of the natural product have already been set. Such work is ongoing and will be reported in due course. 
